Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks’ portfolio and pimicotinib. SpringWorks’ rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN.